AAC
Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Stiefel, U.
Right arrow Articles by Donskey, C. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Stiefel, U.
Right arrow Articles by Donskey, C. J.
Antimicrobial Agents and Chemotherapy, December 2005, p. 5190-5191, Vol. 49, No. 12
0066-4804/05/$08.00+0     doi:10.1128/AAC.49.12.5190-5191.2005
Copyright © 2005, American Society for Microbiology. All Rights Reserved.

LETTER TO THE EDITOR

Orally Administered Recombinant Metallo-ß-Lactamase Preserves Colonization Resistance of Piperacillin-Tazobactam-Treated Mice


   LETTER
Top
 Letter
References
 
Antibiotics that are excreted into the intestinal tract may disrupt colonization resistance (i.e., the ability of the indigenous microflora to provide resistance against colonization by potentially pathogenic microorganisms) (1, 5). Because antibiotic activity within the intestinal lumenis is not needed for the treatment of most infections, we hypothesized that the enzymatic inactivation of the portion of antibiotic that is excreted into the intestinal tract would result in the preservation of colonization resistance during parenteral antibiotic therapy. We previously demonstrated that an orally administered recombinant class A ß-lactamase preserved the colonization resistance of piperacillin-treated mice against nosocomial pathogens (4). Here, we show that a recombinant class B metallo-ß-lactamase that is resistant to tazobactam inactivation preserves colonization resistance during treatment with the more widely used broad-spectrum antibiotic piperacillin-tazobactam.

Targeted recombinant ß-lactamase 2 (TRBL-2) containing amino acid residues 31 to 257 of the metalloenzyme of a clinical Bacillus cereus isolate (98ME 1552 from Helsinki University Hospital) was overproduced in Bacillus subtilis using a bacillar secretion vector (4). The hydrolysis rate of TRBL-2 for piperacillin with or without tazobactam was 275 µg/minute/µg of enzyme. Individually housed female CF-1 mice weighing 25 to 30 g (Harlan Sprague-Dawley, Indianapolis, Indiana) were used to examine the efficacy of TRBL-2 in the preservation of colonization resistance against vancomycin-resistant enterococci (VRE). At 24 h and again at 12 h prior to the orogastric inoculation of 104 CFU of VRE strain C68 (4), mice received either subcutaneous (0.2 ml) and orogastric (0.5 ml) phosphate-buffered saline (PBS), subcutaneous piperacillin-tazobactam (4 mg) and orogastric PBS, subcutaneous piperacillin-tazobactam (4 mg) and orogastric TRBL-2 (60 mg/kg of body weight), or subcutaneous piperacillin-tazobactam (4 mg) and orogastric TRBL-2 (60 mg/kg) that had been inactivated by boiling for 10 min. Stool VRE density was monitored as previously described (2). Denaturing gradient gel electrophoresis (DGGE) of PCR-amplified bacterial rRNA genes was performed on stool samples collected 3 days after the inoculation of VRE in order to monitor changes in the indigenous microflora (3, 4). One-way analysis of variance was performed to compare VRE densities among treatment groups, with P values adjusted for multiple comparisons using the Scheffé correction. DGGE similarity indices were compared using Student's t test. Computations were performed using Stata software (version 5.0; Stata, College Station, Texas).

Mice treated with piperacillin-tazobactam developed high-density VRE stool colonization; saline controls and mice treated with piperacillin-tazobactam in conjunction with TRBL-2 did not (P < 0.001) (Fig. 1). The protective effect of TRBL-2 was eliminated by heat inactivation. DGGE analysis showed that piperacillin-tazobactam caused a significant disruption of the indigenous microflora but that piperacillin-tazobactam in conjunction with TRBL-2 caused a relatively minor alteration of the microflora (mean similarity indices of mice treated with piperacillin-tazobactam and mice treated with piperacillin-tazobactam and TRBL-2 in comparison to those of saline controls were 33% and 86%, respectively; P < 0.001) (Fig. 2).



View larger version (18K):
[in this window]
[in a new window]
  		FIG. 1. Efficacy of oral ß-lactamase in preventing piperacillin-tazobactam-induced overgrowth of VRE. The densities (log10 CFU/g) of stool VRE are shown after the orogastric inoculation of 104 CFU of VRE on day 0. Prior to inoculation, none of the mice had detectable levels of VRE (level of detection, ~2 log10 CFU/g stool). Treatment with subcutaneous piperacillin-tazobactam ({blacksquare}) resulted in high-density VRE colonization, whereas treatment with normal saline ({circ}) or subcutaneous piperacillin-tazobactam in conjunction with orogastric ß-lactamase ({blacktriangleup}) did not. Inactivation of the ß-lactamase by boiling ({square}) resulted in a loss of efficacy. The horizontal bars represent standard errors.

 


View larger version (131K):
[in this window]
[in a new window]
  		FIG. 2. DGGE analysis of stool microflora of individual mice. Lane 1, controls containing rRNA genes amplified from strains of Bacteroides thetaiotaomicron, Bacteroides uniformis, and Escherichia coli (top to bottom); lanes 2 to 4, saline control mice; lanes 5 to 7, piperacillin-tazobactam-treated mice; lanes 8 to 10, piperacillin-tazobactam- plus ß-lactamase-treated mice.

 
These findings provide further evidence that oral ß-lactamase treatment may be an effective means to preserve colonization resistance during therapy with broad-spectrum, parenteral ß-lactam antibiotics. Additional studies are needed to determine the efficacy of this strategy as a means to limit the dissemination of nosocomial pathogens in humans.


   ACKNOWLEDGMENTS
 
This work was supported by a Research Career Development Award from the Department of Veterans Affairs to C.J.D.


   REFERENCES
Top
 Letter
 References
 

  1. Donskey, C. J., T. K. Chowdhry, M. T. Hecker, C. K. Hoyen, J. A. Hanrahan, A. M. Hujer, R. A. Hutton-Thomas, C. C. Whalen, R. A. Bonomo, and L. B. Rice. 2000. Effect of antibiotic therapy on the density of vancomycin-resistant enterococci in the stool of colonized patients. N. Engl. J. Med. 343:1925-1932.[Abstract/Free Full Text]
  2. Donskey, C. J., J. A. Hanrahan, R. A. Hutton, and L. B. Rice. 1999. Effect of parenteral antibiotic administration on persistence of vancomycin-resistant Enterococcus faecium in the mouse gastrointestinal tract. J. Infect. Dis. 180:384-390.[CrossRef][Medline]
  3. Donskey, C. J., A. M. Hujer, S. M. Das, N. J. Pultz, R. A. Bonomo, and L. B. Rice. 2003. Use of denaturing gradient gel electrophoresis for analysis of the stool microbiota of hospitalized patients. J. Microbiol. Methods 54:249-256.[CrossRef][Medline]
  4. Stiefel, U., N. J. Pultz, J. Harmoinen, P. Koski, K. Lindevall, M. S. Helfand, and C. J. Donskey. 2003. Oral ß-lactamase administration preserves colonization resistance of piperacillin-treated mice. J. Infect. Dis. 188:1605-1609.[CrossRef][Medline]
  5. Vollaard, E. J., and H. A. L. Clasener. 1994. Colonization resistance. Antimicrob. Agents Chemother. 38:409-414.[Free Full Text]
Usha Stiefel
Division of Infectious Diseases
University Hospitals of Cleveland
Case Western Reserve University
Cleveland, Ohio 44106

Jaana Harmoinen
Department of Clinical Veterinary Sciences
University of Helsinki
Helsinki, Finland

Pertti Koski
Susanna Kääriäinen
Nina Wickstrand
Kai Lindevall
IPSAT Therapies
Espoo, Finland

Nicole J. Pultz
Robert A. Bonomo
Marion S. Helfand
Curtis J. Donskey*
Research Service
Louis Stokes Cleveland Veterans Affairs Medical Center
Case Western Reserve University
Cleveland, Ohio 44106

* Phone: (216) 791-3800, ext. 5103, Fax: (216) 229-8509, E-mail: curtisd123{at}yahoo.com

Antimicrobial Agents and Chemotherapy, December 2005, p. 5190-5191, Vol. 49, No. 12
0066-4804/05/$08.00+0     doi:10.1128/AAC.49.12.5190-5191.2005
Copyright © 2005, American Society for Microbiology. All Rights Reserved.




This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Stiefel, U.
Right arrow Articles by Donskey, C. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Stiefel, U.
Right arrow Articles by Donskey, C. J.

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
Clin. Vaccine Immunol. Clin. Microbiol. Rev.
J. Clin. Microbiol. ALL ASM JOURNALS